Physician profile
Paul M Rougraff
NPI 1831176288
$1,295.07
in general payments reported to CMS, 2019-2025
13 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $49.86 · 2021: $294 · 2022: $318 · 2023: $141 · 2024: $124 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $453.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $761.45 | 2019-2025 | Argos, Clareon, Clareon Panoptix Pro |
| Abbvie INC. | $175.96 | 2022-2025 | |
| Arthrex, INC. | $69.88 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $50.02 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $38.56 | 2021 | |
| Novartis Pharmaceuticals Corporation | $32.27 | 2023 | |
| Sight Sciences, INC. | $31.87 | 2021-2024 | Omni Surgical System |
| Horizon Therapeutics Plc | $28.16 | 2022 | |
| Oyster Point Pharma, INC. | $24.84 | 2022 | |
| Glaukos Corporation | $23.38 | 2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Johnson & Johnson Vision Care, INC. | $22.64 | 2023 | Acuvue |
| Thea Pharma INC. | $20.14 | 2023 | Iyuzeh |
| Shire North American Group INC | $15.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Rougraff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.